Assembly Biosciences (NASDAQ:ASMB – Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping the consensus estimate of ($2.12) by $0.55, Zacks reports. The company had revenue of $7.36 million during the quarter, compared to the consensus estimate of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%.
Assembly Biosciences Stock Performance
Shares of ASMB opened at $10.69 on Friday. Assembly Biosciences has a 52-week low of $10.27 and a 52-week high of $19.93. The business has a fifty day moving average of $13.00 and a 200 day moving average of $15.18.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.
Insider Buying and Selling at Assembly Biosciences
In other news, Director Michael Houghton purchased 3,202 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $15.61 per share, with a total value of $49,983.22. Following the purchase, the director now owns 3,202 shares in the company, valued at approximately $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.10% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
See Also
- Five stocks we like better than Assembly Biosciences
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- Insider Trading – What You Need to Know
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
